HiberCell to Present Preclinical Data Demonstrating the Enhanced Antitumor Activity of HC-7366 in Combination with VEGFR-TKIs in Clear Cell Renal Cell Carcinoma (ccRCC)ROSEVILLE, Minn., April 14, 2026 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the preclinical poster presentation titled, Combination of the GCN2 activator HC-7366 with VEGFR-TKI results in greater efficacy than VEGFR-TKI alone or VEGFR-TKI/HIF-2i combinations in ccRCC which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place April 17-22 in San Diego, California. The abstract is now available on the AACR website.
HiberCell Announces Successful Completion of Dose Escalation and Enrollment Update for Ph1b Study Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in Advanced ccRCCBOSTON, May 27, 2025 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the successful completion of the dose escalation portion of its Phase 1b study evaluating HC-7366—an activator of the integrated stress response (ISR) kinase GCN2—in combination with Merck’s (known as MSD outside the US and Canada) oral hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor, WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC).
HiberCell Receives FDA Fast Track Designation for HC-7366 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (AML)BOSTON, Oct. 23, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to HC-7366 for the treatment of adult patients with relapsed or refractory acute myeloid leukemia.
HiberCell Announces First Patient Dosed in Phase 1b Clinical Trial, Evaluating HC-7366 in Combination with Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia (AML)BOSTON, May 28, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address advanced cancer and cancer resistance, is pleased to announce the first patient dosed in a clinical trial evaluating HC-7366 in combination with standard of care agents venetoclax and azacitidine for advanced acute myeloid leukemia (AML).
HiberCell Announces First Patient Dosed in Clinical Collaboration with Merck, Evaluating HC-7366 in Combination with WELIREG® (belzutifan) in patients with advanced ccRCCBOSTON, May 01, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, is pleased to announce the dosing of the first patient in a Phase 1b study evaluating HC-7366, an activator of integrated stress response (ISR) Kinase GCN2, in combination with Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor WELIREG® (belzutifan) for the treatment of advanced clear cell renal cell carcinoma (ccRCC).
HiberCell Announces Recent Publication and Poster Presentations for its Novel GCN2 Activator, HC-7366NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced the publication of “Discovery of HC-7366: An Orally Bioavailable and Efficacious GCN2 Kinase Activator” in the Journal of Medicinal Chemistry along with two poster presentations on this same molecule which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place in San Diego, California. This publication and abstracts are now available online and on the AACR website, respectively.
HiberCell Announces Presentation at ASH, Highlighting Preclinical Data for HC-7366 with Standard of Care Agents in Acute Myeloid Leukemia (AML)NEW YORK, Dec. 15, 2023 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced data from a poster presentation at the 65th ASH Annual Meeting and Exposition, which took place from December 9-12th, 2023 in San Diego, California.
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR Kinase GCN2, in Combination with WELIREG® (belzutifan) in a Phase 1b Study of Patients with Clear Cell Renal Cell Carcinoma (ccRCC)NEW YORK, Dec. 05, 2023 (GLOBE NEWSWIRE) -- HiberCell, Inc., a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced a clinical collaboration with Merck (known as MSD outside the United States and Canada) to evaluate HC-7366, HiberCell’s first-in-class, potent and selective activator of the general control nonderepressible 2 (GCN2) kinase, in combination with WELIREG® (belzutifan), Merck’s oral hypoxia-inducible factor-2α (HIF-2α) inhibitor, for the treatment of clear cell renal cell carcinoma (RCC).
HiberCell Announces Successful Completion and Interim Results of Phase 1 Study of Novel PERK Inhibitor, HC-5404, in Solid Tumors and Maps Forward Path as Monotherapy and in CombinationsNEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company dedicated to addressing mechanisms of treatment resistance, cancer relapse, and metastasis, today announced the successful completion of its Phase 1 study of the novel PERK inhibitor, HC-5404, in solid tumors along with two pre-clinical publications in one of the leading journals of AACR, Clinical Cancer Research (CCR).
HiberCell Doses First Patient in Phase 1b Study Exploring Novel Combination of Odetiglucan and CD40 Agonistic Monoclonal Antibody (CDX-1140) in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) in the Maintenance SettingBOSTON, May 22, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address cancer relapse, metastasis, and resistance, today announced dosing of the first patient in a Phase 1b clinical trial investigating the effects of odetiglucan, a first-in-class immunomodulatory agent, in combination with the CD40 agonistic monoclonal antibody, CDX-1140, in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) in the maintenance setting. Odetiglucan is a systemically administered Dectin-1 agonist that has been observed to modulate both the innate and adaptive immune systems. CDX-1140 is a potent CD40 agonist antibody developed by Celldex Therapeutics specifically designed to balance good systemic exposure and safety with potent biological activity.
HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023BOSTON, March 24, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis, treatment resistance, and cancer relapse, today announced three pre-clinical poster presentations which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida. The abstracts are now available on the AACR website.
HiberCell Maps Forward Path for Novel GCN2 Activator, HC-7366 in Acute Myeloid Leukemia (AML)BOSTON, Feb. 22, 2023 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis, treatment resistance and cancer relapse, today announced data from a recent poster presentation at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome, which took place from January 23-25, 2023 in Austin, Texas. The Company also announced the recently cleared Investigational New Drug (IND) application for the initiation of clinical studies of HC-7366, the Company’s GCN2 stress response protein kinase modulator for the treatment of AML.
HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual MeetingNEW YORK, Nov. 02, 2022 (GLOBE NEWSWIRE) -- HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today announced two clinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.
